Anti-Ri humanized monoclonal antibody, application thereof and detection method based on anti-Ri humanized monoclonal antibody
By designing a humanized monoclonal antibody with high specificity and high affinity, the problem of insufficient positive reference products for detecting Ri autoantibodies in paraneoplasty of nervous system is solved, and the Nova-1 and Nova-2 proteins/polypeptides are achieved. The effective identification and detection of the product provides reliable positive control, meets the needs of diagnostic kits, and improves the quality control and scientific research value of the product.
Patent Information
- Application Number
- CN202411093379.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-09
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2044-08-09
AI Technical Summary
The existing detection kit for detecting Ri autoantibodies in parane tumor syndrome in nervous system has design problems, especially the lack of reliable positive reference products, which leads to difficulties in product quality control and long-term quality control, and humanized chimeric monoclonal antibodies Studies on Nova-1 and Nova-2 antigens have not been achieved.
A humanized monoclonal antibody 3F5 was designed with high specificity and good affinity, able to recognize Ri proteins, and used to detect Nova-1 and Nova-2 proteins/polypeptides, as a positive control for the detection kit, meeting the diagnostic reagents. and its production is achieved through vector and host cells.
This monoclonal antibody is easy to preserve and modify, can meet the positive control needs of the anti-Nova-1/Nova-2 autoantibodies detection kit, and provides quantitative and traceable reference products, solving the problem of insufficient positive serum and improving the Product quality control and scientific research guidance significance.
Smart Images

Figure CN118994384A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of monoclonal antibody preparation, and relates to humanized anti-Ri monoclonal antibodies and applications thereof and detection methods based thereon, and specifically to humanized chimeric anti-Ri monoclonal antibodies and applications thereof and methods for detecting Nova-1 / Nova-2 proteins / polypeptides using the same. Background Art
[0002] Paraneoplastic neurological syndrome (PNS) is a special autoimmune disease of the nervous system, and its mechanism is an immune-mediated tumor afar effect. PNS has a variety of autoantibodies, including anti-Hu (also known as type 1 anti-neuronal nuclear autoantibody, ANNA-1), anti-Ri (also known as type 2 anti-neuronal nuclear autoantibody, ANNA-2), anti-Yo (also known as Purkinje cell antibody type 1, PCA1; or cerebellar degeneration-related protein CDR2) autoantibodies and other autoantibodies. Among them, anti-Ri autoantibody is one of the diagnostic antibodies for paraneoplastic cerebellar ataxia, which is mainly seen in brain, brainstem, spinal cord dysfunction, ataxia, rarely in sensory, motor sensory and motor neuron diseases, and commonly in breast cancer, small cell lung cancer, bladder cancer and other related cancers. Detection of anti-Ri autoantibodies is very necessary for the prevention and treatment of paraneoplastic cerebellar ataxia, because both Nova-1 and Nova-2 proteins are target antigens for anti-Ri antibodies, so the detection of anti-Nova-1 antibody positive, anti-Nova-2 antibody positive, or anti-Nova-1 and anti-Nova-2 positive at the same time are all called anti-Ri autoantibody positive. The target antigen Nova-1 and Nova-2 proteins have extremely high homology sequences, among which Nova-1 is mainly expressed in the cerebellum and spinal cord, and Nova-2 is mainly expressed in the cortex. In vascular endothelial cells, Nova-2 is essential for angiogenesis, while in adipocytes, Nova-1 is involved in the regulation of thermogenesis and obesity. In many cancers, Nova-1 and Nova-2 activate carcinogenic effects through interactions with specific miRNAs and other mechanisms, promoting cell proliferation, colony formation, migration and invasion.
[0003] At present, the detection kits for autoantibodies of nervous system autoimmune diseases are developing rapidly and the market demand is strong. There are already detection kits for Ri autoantibodies in paraneoplastic syndrome. Most of the detections for Ri autoantibodies are Nova-1 autoantibody detection or simultaneous detection of Nova-1 and Nova-2 autoantibodies. Whether it is the detection of one or two autoantibodies, or whether the detection kits are prepared by various methods such as cell-based immunofluorescence, immunospot, colloidal gold or ELISA, there are many difficulties in the product design and development stage. In addition, there are no national standard products or industry standard products on the market as reference products for such products. Enterprises can only use positive and negative serum to establish their own reference products for product performance verification, quality control and other research. However, due to the complex serum composition and the low incidence of such diseases, the small number of positive serum is not easy to collect, which cannot meet the requirements of preliminary research and long-term quality control of products.
[0004] Humanized chimeric antibodies are an important achievement in the field of antibody engineering. They are produced by inserting the light chain and heavy chain variable region (V region) genes of heterologous monoclonal antibodies (such as mouse monoclonal antibodies) into expression vectors containing human antibody constant regions (C regions) through DNA recombination technology, and then transforming mammalian cells to express antibodies. The V region of this antibody molecule is heterologous, while the C region is human, so it is called a chimeric antibody. While retaining the ability of the parent antibody to specifically bind to the antigen, humanized chimeric antibodies greatly reduce the immunogenicity of heterologous antibodies. Since humanized chimeric antibodies can specifically recognize the corresponding antigens, they can replace the function of positive serum to a certain extent, and determine the concentration through protein quantification and the titer through antibody titer testing, thereby obtaining quantifiable and traceable corporate reference material raw materials.
[0005] Currently, there is still a research gap in the development of anti-Ri monoclonal antibodies that can simultaneously recognize Nova-1 and Nova-2 antigens in paraneoplastic syndrome test kits using human-mouse chimeric monoclonal antibodies. Summary of the invention
[0006] In order to overcome the shortcomings of the above-mentioned prior art, the object of the present invention is to provide an anti-Ri monoclonal antibody and its application and a method for detecting Nova-1 protein / polypeptide or Nova-2 protein / polypeptide using the same. The monoclonal antibody has strong specificity and high sensitivity, can meet the requirements of positive reference materials in diagnostic kits, is easy to store and transform, and wherein the antibody has the ability to recognize the target antigen Ri in the human body.
[0007] In order to achieve the above object, the present invention adopts the following technical solutions:
[0008] The present invention discloses an anti-Ri monoclonal antibody, which is named as humanized monoclonal antibody 3F5, and comprises a light chain and a heavy chain;
[0009] The variable region of the heavy chain includes three heavy chain complementary determining regions CDR1, CDR2 and CDR3, the amino acid sequence of the heavy chain complementary determining region CDR1 is shown in SEQ ID NO.1, the amino acid sequence of the heavy chain complementary determining region CDR2 is shown in SEQ ID NO.2, and the amino acid sequence of the heavy chain complementary determining region CDR3 is shown in SEQ ID NO.3;
[0010] The variable region of the light chain includes three light chain complementary determining regions CDR1, CDR2 and CDR3, the amino acid sequence of the light chain complementary determining region CDR1 is shown in SEQ ID NO.4, the amino acid sequence of the light chain complementary determining region CDR2 is shown in SEQ ID NO.5, and the amino acid sequence of the light chain complementary determining region CDR3 is shown in SEQ ID NO.6.
[0011] Preferably, the amino acid sequence of the heavy chain variable region of the humanized monoclonal antibody 3F5 is shown as SEQ ID NO.7, and the amino acid sequence of the light chain variable region is shown as SEQ ID NO.8.
[0012] Further preferably, the nucleotide sequence encoding the heavy chain variable region of the humanized monoclonal antibody 3F5 is shown as SEQ ID NO.9; the nucleotide sequence encoding the light chain variable region of the humanized monoclonal antibody 3F5 is shown as SEQ ID NO.10.
[0013] Preferably, the monoclonal antibody comprises a light chain having a complementarity determining region of an amino acid sequence that is at least 75% identical to the sequence of the variable region of the light chain, and the complementary domain of the light chain retains the ability to bind to the Ri protein; the monoclonal antibody comprises a heavy chain having a complementarity determining region of an amino acid sequence that is at least 75% identical to the sequence of the variable region of the heavy chain, and the complementary domain of the heavy chain retains the ability to bind to the Ri protein.
[0014] The invention also discloses a vector, which comprises the nucleotide sequence of the anti-Ri monoclonal antibody.
[0015] The present invention also discloses a host cell, which comprises the above-mentioned vector.
[0016] The present invention also discloses the use of the above-mentioned anti-Ri monoclonal antibody, vector or host cell in preparing a reagent / kit for detecting Ri protein.
[0017] The present invention also discloses the use of the above-mentioned anti-Ri monoclonal antibody, vector or host cell in preparing reagents / kits for diagnosing and / or prognosticating human paraneoplastic movement disorders.
[0018] The present invention also discloses a method for detecting Nova-1 protein / peptide or Nova-2 protein / peptide, wherein a biological sample is contacted with the above-mentioned anti-Ri monoclonal antibody to detect the Nova-1 protein / peptide or Nova-2 protein / peptide in the biological sample.
[0019] Preferably, the biological sample includes but is not limited to plasma, whole blood, serum, tissue, cells, or lysates of tissues and cells containing Nova-1 protein / polypeptide or Nova-2 protein / polypeptide.
[0020] Compared with the prior art, the present invention has the following beneficial effects:
[0021] The present invention has designed and obtained for the first time a monoclonal antibody against Ri with high specificity and good affinity, and the antibody sequence is the core invention of the present invention. The monoclonal antibody against Ri can be used to detect antigens, and can also be used as a positive control of a detection kit, that is, it can be used for other scientific research such as Nova-1 or Nova-2 antigen detection, and can also meet the needs of the anti-Nova-1 / Nova-2 autoantibody detection kit for positive controls, is easy to store and transform, and is easy to control the quality of the antibody production process. Specifically, it can be detected whether the protein expression is up-regulated or down-regulated, and the changes in the expression of some proteins have certain significance for some related diseases, so it has very good application value and very important scientific research guidance significance. BRIEF DESCRIPTION OF THE DRAWINGS
[0022] Figure 1 The purification result of N-6his protein;
[0023] Figure 2a The results of antibody titer determination of immunized mice for Nova-1 protein;
[0024] Figure 2b The results of Nova-2 protein antibody titer determination in immunized mice;
[0025] Figure 3 The results of subtype identification of hybridoma cell line 3F5. Each group of data in the figure represents total IgG, IgG1, IgG2a, IgG2b, IgG3, IgM, Ig kappa chain and Ig lambda chain from left to right;
[0026] Figure 4a The results of the titer determination of Ri-3F5 human-mouse chimeric antibody;
[0027] Figure 4b The eyeball blood of rat No. 3 was used as a control for the determination of antibody titer;
[0028] Figure 5Dot blot was used to verify the function of anti-Ri-3F5 human-mouse chimeric antibody;
[0029] Figure 6a To verify the function of anti-Ri human-mouse chimeric antibody by immunofluorescence assay;
[0030] Figure 6b This is the comparison result of positive signal by immunofluorescence method;
[0031] Figure 7 Immunoblotting was used to verify the function of the anti-Ri human-mouse chimeric antibody. DETAILED DESCRIPTION
[0032] In order to enable those skilled in the art to better understand the scheme of the present invention, the technical scheme in the embodiments of the present invention will be clearly and completely described below in conjunction with the drawings in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work should fall within the scope of protection of the present invention.
[0033] It should be noted that the terms "first", "second", etc. in the specification and claims of the present invention and the above-mentioned drawings are used to distinguish similar objects, and are not necessarily used to describe a specific order or sequence. It should be understood that the data used in this way can be interchanged where appropriate, so that the embodiments of the present invention described herein can be implemented in an order other than those illustrated or described herein. In addition, the terms "including" and "having" and any variations thereof are intended to cover non-exclusive inclusions, for example, a process, method, system, product or device that includes a series of steps or units is not necessarily limited to those steps or units that are clearly listed, but may include other steps or units that are not clearly listed or inherent to these processes, methods, products or devices.
[0034] The present invention is further described in detail below in conjunction with the accompanying drawings:
[0035] Unless otherwise noted, scientific and technical terms used in connection with the present invention shall have the meanings commonly understood by those of ordinary skill in the art.
[0036] The term "antibody" as used herein refers to immunoglobulin molecules and the immunologically active portion of immunoglobulin molecules, i.e., molecules containing an antigen binding site that immunologically binds to an antigen. It includes, but is not limited to, polyclonal antibodies, monoclonal antibodies, chimeric antibodies, humanized antibodies, human-mouse chimeric antibodies, single-chain, F ab 、F ab’ and F (ab’)2 Fragments, single-chain FV fragments and F ab Expression library.
[0037] "Monoclonal antibody" refers to a population of antibodies from a single species that contains a unique light chain gene product and a unique heavy chain gene product. Specifically, it means that the complementarity determining regions of monoclonal antibodies are the same in all molecules in the population and can bind to the antigen binding site of a specific epitope of an antigen.
[0038] "Antigen binding site" refers to the part of an antibody molecule that participates in antigen binding. The antigen binding site is formed by amino acid residues in the N-terminal variable (V) region of the heavy (H) and light (L) chains.
[0039] "Chimeric antibody" refers to an antibody molecule that is spliced from the V region gene of other non-human antibodies and the C region gene of a human antibody, which is then inserted into a vector and transfected into myeloma tissue for expression.
[0040] The term "chimeric antibody" means an antibody in which the sequences of the H chain variable region and the L chain variable region (VH and VL) are derived from non-human animal species and in which the constant region sequences (CH and CL) are derived from humans. The sequence of the variable region is preferably derived from, for example, an animal species that allows easy preparation of hybridomas, such as mice, rats, rabbits, etc.
[0041] The term "humanized monoclonal antibody" refers to replacing the CDR region of a human antibody with the CDR region of an antibody from a non-human animal species, also known as a CDR-grafted antibody. The CDR sequence of an antibody from a non-human animal species is preferably derived from, for example, an animal species that allows easy preparation of hybridomas, such as mice, rats, rabbits, etc.
[0042] Example 1 Preparation of anti-Ri monoclonal antibody hybridoma cells
[0043] 1. Purification of N-6his protein
[0044] The human Nova-1 gene sequence, NCBI sequence number NM_002515.3, and the human Nova-2 gene sequence, NCBI sequence number NM_002516.4, were obtained from the GenBank sequence database. By comparing the homology of the Nova-1 and Nova-2 protein sequences, it was found that the sequence homology between the 40th to 149th positions of the Nova-1 protein amino acid sequence and the 23rd to 132th positions of the Nova-2 protein amino acid sequence was 85.45%. Therefore, the 40th to 149th positions of the Nova-1 protein amino acid sequence were selected, and a 6his tag sequence was added to the C-terminus of the gene. The gene sequence was synthesized by Jinweizhi Company into the pET-28a vector and named N-6his to obtain the N-6his recombinant vector. The constructed and correctly sequenced plasmid was transferred into the expression competent cells of Escherichia coli ArcticExpress (DE3); a single clone was picked and inoculated into LB medium, and the culture was shaken at 37°C until the OD value was 0.5-1, and a final concentration of 0.5mM IPTG was added for induction, and the expression was carried out overnight at 16°C; the bacteria were collected, ultrasonically disrupted, and the supernatant was collected after centrifugation. The Ri protein expressed by pET-28a was purified by Ni-NTA column affinity chromatography, and the purified protein was recorded as N-6his. The purified protein was dialyzed and concentrated to obtain a high-concentration N-6his protein as an immune antigen. The purification results are shown in Figure 1 shown.
[0045] The same method was used to search for the human Nova-1 gene sequence, the NCBI sequence number was NM_002515.3, and a GST tag sequence was added to the C-terminus of the gene. The gene sequence was synthesized by Jinweizhi Company into the pGEX 4t-1 vector to obtain the Nova-1-GST recombinant vector. The Nova-1 protein expressed by pGEX 4t-1 was purified by GSH column affinity chromatography, and the purified protein was recorded as Nova-1. The purified protein was dialyzed and concentrated to obtain a high-concentration Nova-1 protein, which was used as a detection antigen.
[0046] The same method was used to search for the gene sequence of human Nova-2, the NCBI sequence number was NM_002516.4, and a 6his tag sequence was added to the C-terminus of the gene. The gene sequence was synthesized by Jinweizhi Company into the pET-28a vector to obtain the Nova-2-6his recombinant vector. The Nova-2 protein expressed by pET-28a was purified by Ni-NTA column affinity chromatography, and the purified protein was recorded as Nova-2. The purified protein was dialyzed and concentrated to obtain a high-concentration Nova-2 protein, which was used as a detection antigen.
[0047] 2. Immunization of mice
[0048] 40ug of purified N-6his recombinant protein in step 1 was used as an immunogen to immunize three Balb / c mice. The antigen and Freund's adjuvant were mixed in equal volumes at a ratio of 1:1 and fully ground into a water-in-oil emulsion. The injection volume for each mouse was 100uL of a mixture of antigen and Freund's adjuvant (antigen volume was 40ug / mouse), and the injection site was the back. The second immunization was performed 14 days after the first immunization, and the third immunization was performed 14 days after the second immunization. For the subsequent two immunizations, the dose, method, and route of injection of the antigen were the same as those for the first immunization.
[0049] 3. Detection of antibody production in immunized mice
[0050] Three days after the immunization, blood was collected from the mouse eyeballs, and the serum was collected by centrifugation. The titer was tested using ELISA, and mice with high titers were selected for booster immunization. The specific operation of ELISA titer detection is as follows: use pH9.6 carbonate buffer to coat the purified Nova-1 protein and Nova-2 protein as detection antigens, with a concentration of 100 ng / well, and coat overnight at 4°C; the next day, wash 3 times with 0.1M PBST, 3 minutes each time, and pat dry; add blocking protein (2% BSA solution), 200uL / well, incubate at 37°C for 1h; wash 3 times with 0.1M PBST, 3 minutes each time, and pat dry; dilute the sera of 3 immunized mice and the serum of a normal control mouse with PBS in multiple ratios, at 1:50, 1:150, 1:450, 1:1350, 1:4050, 1:12150, 1:36450, 1:109350, add 100ul to each well, incubate at 37°C for 1h; wash 3 times with 0.1M PBST, 3 minutes each time, and pat dry; use goat anti-mouse IgG-HRP Diluted 1:5000 (manufacturer: Jackson), incubated at 37°C for 30 min; washed 3 times with 0.1 M PBST, 3 min each time, and patted dry; added TMB for color development for 10 min, terminated with 2 M H2SO4, and measured absorbance at 450 nm.
[0051] Test results such as Figure 2a and Figure 2b As shown, a comprehensive comparison of the titers of serum antibodies from the three immunized mice showed that only mouse No. 3 had strong specificity for both Nova-1 and Nova-2 proteins, so mouse No. 3 was selected for subsequent experiments.
[0052] 4. Cell fusion and hybridoma cell screening
[0053] 4.1 Preparation of feeder cells and myeloma cells: Take macrophages from the ascites of ordinary mice as feeder cells for culture. Take feeder cells from the ascites of 4-6 mice and plate them on 10 96-well plates. Prepare hybridoma cells after 2 days of culture. Collect myeloma cells SP2 / 0 with good growth and a cell density of 90% in the logarithmic growth phase, a total of 10 dishes. Centrifuge and discard the supernatant, resuspend the cells in DMEM medium and count them.
[0054] 4.2 Preparation of spleen cells: No. 3 mice were boosted with intraperitoneal injection of antigens. Three days later, the eyeballs were removed to collect blood for serum separation, and the blood was rinsed with running water and placed in a 75% ethanol solution for 10 minutes. The spleen of the mouse was aseptically removed and placed in a 200-mesh disposable sterile filter. The spleen was cut into pieces with sterile surgical scissors and ground with the piston handle of a 50mL sterile syringe to obtain a single spleen cell suspension.
[0055] 4.3 Cell fusion: Prepare a 37℃ water bath in the clean bench and preheat it in advance. Add the pre-cultured SP2 / 0 cells and spleen cells with a cell density of 90% in a 1:10 ratio into a 50ml centrifuge tube and mix well. Centrifuge at 500g for 10min, aspirate the supernatant, flick the bottom of the centrifuge tube to loosen the cell pellet slightly; slowly drip 1mL of 45% PEG1450 solution preheated to 37℃ within 90s; and shake the centrifuge tube gently continuously; the centrifuge tube is in a 37℃ water bath during the whole process. Then add DMEM culture medium to the cell mixture at a uniform speed, drip 1mL dropwise in the first minute, add 2mL in the second minute, add 3mL in the third minute, add 4mL in the fourth minute, add 5mL in the fifth minute, and shake while adding in a 37℃ water bath. Then incubate at 37℃ for 15min, centrifuge at 500g for 5min, and remove the supernatant. Add 5 ml of DMEM medium containing HAT, gently suspend the precipitated cells, and finally add DMED medium containing HAT to about 100 mL. Dispense into a 96-well cell culture plate with feeder cells, 100uL / well, and then place the culture plate in a 37°C, 5% CO2 incubator for culture. Add 100uL of HAT culture medium to each well on the second day after fusion, and then half-change the HAT culture medium every 2-3 days, and screen after about 2 weeks of culture.
[0056] 4.4 Screening of positive hybridoma cells: Observe the growth of hybridoma cells. After 7 days, when the cell culture supernatant turns yellow, take an appropriate amount of cell supernatant for ELISA antibody detection. According to the ELISA results, select clones with high OD values, which are more than twice higher than the negative control, and spread on 96-well plates for the first subclone screening. After 7-10 days, perform ELISA to detect antibodies again, select clones with high OD values, spread on 96-well plates, and perform the second subclone screening, so that there is about 1 cell per well; after 7-10 days of culture, perform ELISA to detect antibodies again, select clones with high OD values, spread on 96-well plates, and perform the third subclone screening, so that there is about 1 cell per well. Select several clones with high OD values for further verification. Finally, a positive clone cell was screened out and named: 3F5.
[0057] 4.5 Identification of subtypes of positive hybridoma cells: Re-coat the purified N-6his protein as an antigen to detect the subtype of 3F5 monoclonal cells. The antigen coating concentration was 100 ng / well and coated overnight at 4°C. The next day, wash 3 times with 0.1M PBST, 3 min each time, and pat dry. Add blocking protein (2% BSA solution), 200uL / well, incubate at 37°C for 1h. Wash 3 times with 0.1M PBST, 3 min each time, and pat dry. Add 100ul / well of hybridoma cell supernatant, and use 1:1000 dilution of No. 3 mouse eyeball blood as a positive control, add 100ul to each well, incubate at 37°C for 1h. Wash 3 times with 0.1M PBST, 3 min each time, and pat dry. Use HRP-labeled secondary antibodies (total IgG / IgG1 / IgG2a / IgG2b / IgG3 / IgM / Kappa chain / lambda chain), antibody diluted 1:5000 (manufacturer: Jackson), incubated at 37℃ for 30min; washed 3 times with 0.1M PBST, 3min each time, patted dry; added TMB for 5min, stopped with 2M H2SO4, and measured absorbance at 450nm. The experimental results are shown in Figure 3 As shown, the heavy chain of 3F5 monoclonal antibody is IgG1, and the light chain is Ig kappa chain.
[0058] Example 2 Identification of anti-Ri monoclonal antibody sequences
[0059] The 3F5 hybridoma cells screened in Example 1 were cultured and expanded, and the cells were lysed with Trizol, and total RNA was extracted from the hybridoma cell lysate (Quick-RNA MicroPrep Kit). RNA was separated by agarose gel electrophoresis, and then 5'RACE was performed to obtain cDNA (Clontech SMARTer RACE 5' / 3'kit), which was used as a template for PCR amplification ( Max DNA Polymerase) was used to extract the antibody variable region cDNA, which was then sequenced by a sequencing company to obtain the heavy chain variable region amino acid sequence and light chain variable region amino acid sequence of the 3F5 monoclonal antibody. The Kabat method was used to mark the heavy chain variable region complementary determining region sequence and the light chain variable region complementary determining region sequence of the 3F5 monoclonal antibody. The relevant sequences are shown in Table 1.
[0060] Table 1
[0061]
[0062]
[0063] Table 2
[0064]
[0065]
[0066] Example 3 Preparation of anti-Ri human-mouse chimeric antibodies
[0067] The heavy chain variable region of monoclonal antibody 3F5 and the human IgG1 heavy chain constant region sequence SEQ ID NO.11 determined by sequencing were connected to the vector pcDNA3.1 and marked as pcDNA3.1-Ri-VH-3F5. The light chain variable region of 3F5 and the human IgG1 light chain constant region sequence SEQ ID NO.12 were connected to the vector pcDNA3.1 and marked as pcDNA3.1-Ri-VL-3F5. The connected recombinant plasmid was sent to Sangon Biotechnology for sequencing. The sequenced recombinant plasmid was extracted and used for cell transfection to prepare antibodies.
[0068] The reconstructed pcDNA3.1-Ri-VH-3F5 plasmid and pcDNA3.1-Ri-VL-3F5 plasmid were co-transfected into Expi293F cells for transient expression (transfection reagent PEI, thermo) to obtain cells transfected with the monoclonal antibody 3F5 plasmid. The supernatant was collected 3 days after transfection, purified using protein A filler, and labeled as Ri-3F5. The Ri-3F5 protein concentration was determined by the BCA method to be 0.1 mg / mL.
[0069] Example 4: Detection of the titer of anti-Ri human-mouse chimeric antibodies
[0070] 1. ELISA to verify the function of anti-Ri human-mouse chimeric antibody
[0071] Use carbonate buffer with a pH value of 9.6 to coat the purified Nova-1 protein and Nova-2 protein as detection antigens, with a concentration of 100 ng / well, and coat overnight at 4°C (the coating solution is 25 mL carbonate buffer, pH 9.6); wash three times with PBST solution the next day, each time for 3 minutes, and pat dry each time; add 2% BSA to cover the wells, and incubate at 37°C for 1 hour; after incubation, wash three times with PBST, each time for 3 minutes, and pat the board to remove excess water each time; incubate the Ri-3F5 human Mouse chimeric antibody and mouse eyeball blood were used as positive controls, and the dilution ratios were 1:1, 1:3, 1:9, 1:27, 1:81, 1:243, 1:729, and 1:2187, respectively. 100 μL of the above dilutions were added to each well, incubated at 37°C for 1 hour, washed 3 times with PBST, 3 minutes each time, and patted dry each time; goat anti-human / goat anti-mouse IgG-HRP secondary antibodies were diluted at a ratio of 1:5000, added to the plate, and incubated at 37°C for 30 minutes; after incubation, washed 3 times with PBST, patted dry, TMB was added for color development for 3 minutes, 2M H2SO4 was terminated, and the absorbance was measured at 450nm. The experimental results are shown in Figure 4a and Figure 4b , 3F5 monoclonal antibody can specifically recognize Nova-1 and Nova-2 antigens, and when the antigen coating amount is 100 ng / well, the titer of Ri-3F5 human-mouse chimeric antibody can reach ≥1:2187.
[0072] 2. Dot Blot Verification of the Function of Anti-Ri Human-mouse Chimeric Antibodies
[0073] Anti-human Fab antibody (manufacturer: Sigma) was diluted to a concentration of 100 ng / μL as a quality control point (Ctrl), Nova-1 protein, Nova-2 protein and Yo control protein were diluted to a concentration of 40 ng / μL as detection proteins, 0.8 μL of each sample was taken with a micropipette, and bound to the NC membrane in the shape of a right-angled trapezoid in the form of a circular imprint, distributed as follows Figure 5As shown in the notes, dried at 37°C for 30 min, placed in a 24-well plate, and incubated with 0.1 mg / mL Ri-3F5 human-mouse chimeric antibody purified in Example 4 (1:200 dilution), Ri antibody-positive (i.e., Nova-1 antibody and Nova-2 antibody are both positive) patient serum (1:10 dilution), Nova-1 antibody-positive patient serum (1:10 dilution), Nova-2 antibody-positive patient serum (1:10 dilution), No. 3 immune mouse eyeball blood (1:200 dilution), and 0.5 mg / mL Nova-1 commercial antibody (1:1000 dilution, manufacturer: thermo) for 300 min. ul / well, incubate on a shaker at room temperature for 30 minutes, wash with 1% NaCl, 4 minutes / time, and wash twice in total; dilute AP-labeled goat anti-human / mouse / rabbit IgG secondary antibody 2000 times (manufacturer: Jackson), add to the corresponding wells, incubate on a shaker at room temperature for 30 minutes, wash with 1% NaCl, 4 minutes / time, and wash twice in total; after removing the washing solution in the well, add 50-fold diluted BCIP / NBT substrate, 300μL / well, stand at room temperature in the dark for 4 minutes, discard the substrate dilution in the well, rinse the test strip with distilled water 1-2 times, take it out to dry or dry it at 37℃-45℃, observe the color development, and the results are as follows Figure 5 shown.
[0074] According to the results, it can be seen that the modified Ri-3F5 human-mouse chimeric antibody and Ri positive patient serum can effectively recognize Nova-1 and Nova-2 antigens and form visible spots under the conditions of incubation with the same antigen and the same AP-labeled goat anti-human IgG secondary antibody, while the No. 3 immune mouse serum and Nova-1 commercial antibody need to be incubated with AP-labeled goat anti-mouse / rabbit IgG secondary antibody to form visible spots, and the No. 3 immune mouse serum does not recognize anti-human Fab antibodies and cannot meet the requirements of the quality control points. Although the Nova-1 commercial antibody recognizes anti-human Fab antibodies, it is non-specific recognition. Due to the different species of the incubated secondary antibodies and the recognition of the quality control points, the No. 3 immune mouse serum and the Nova-1 commercial antibody cannot meet the requirements as a substitute for patient serum, while the modified Ri-3F5 human-mouse chimeric antibody can be used as a substitute for positive serum to meet the requirements of the reference product in the diagnostic kit of the present invention.
[0075] 3. Immunofluorescence verification of the function of anti-Ri human-mouse chimeric antibodies
[0076] By PCR or artificial synthesis, the human Nova-1 gene sequence and the human Nova-2 gene sequence were connected to pCDNA3.1 by molecular cloning to obtain the corresponding recombinant vector. The constructed recombinant vector was prepared for use after sequencing. 293T cells with 6 cm × 6 cm crawling slides were spread on the bottom of the culture dish in a 10% FBS-DMEM high-glucose culture medium at 37°C and 5% CO2 cell culture incubator. When the cell density reached 30% to 40%, PEI transfection reagent (manufacturer: thermo, item number: BMS1003) was used to transfect pcDN A3.1-Nova-1 recombinant vector, pcDNA3.1-Nova-2 recombinant vector and empty pCDNA3.1 were transfected into 293T cells and labeled respectively; the cells grown for 48 h after transfection were washed twice with PBS, fixed with acetone for 5 min, washed twice with PBS, dried at 45°C for 30 min, and the cell slides were cut into 2.5 mm × 2.5 mm pieces and attached to glass slides to prepare Nova-1 overexpressing cell slides, Nova-2 overexpressing cell slides and pCDNA3.1 control slides as detection chips.
[0077] The anti-Ri-3F5 human-mouse chimeric antibody purified in Example 3 was diluted at a ratio of 1:100 using PBST, and the serum of Ri-positive patients was diluted at a ratio of 1:10, and incubated with Nova-1 overexpressing, Nova-2 overexpressing cell slides and pCDNA3.1 control slides, respectively, incubated at room temperature for 1 hour, washed 3 times with PBST, each time for 5 minutes, added with Alexa Fluor 594-labeled goat anti-human IgG (manufacturer: Jackson) diluted 1:200, incubated at room temperature for 30 minutes, and washed 3 times with PBST, each time for 5 minutes; observed under a microscope, the results are as follows Figure 6a and Figure 6b As shown, from Figure 6a The results show that the modified Ri-3F5 human-mouse chimeric antibody and Ri patient serum can produce obvious fluorescent signals with both Nova-1 overexpressing cell slides and Nova-2 overexpressing cell slides under the same incubation conditions. In addition, compared with the positive serum, the fluorescent cell morphology produced by the modified Ri-3F5 human-mouse chimeric antibody is a typical Nova-1 positive signal and a typical Nova-2 positive signal. Figure 6bAs shown, it shows that Ri-3F5 human-mouse chimeric antibody can recognize both overexpressed Nova-1 protein and overexpressed Nova-2 protein, and has obvious humanized species advantages, and can be used as a serum substitute to meet the needs of long-term detection reagents. This monoclonal antibody can also help computer artificial intelligence technology to process indirect immunofluorescence images. Using this monoclonal antibody for a variety of experiments can not only enrich the number of positive images, but also add more typical positive cell morphology, making the indirect immunofluorescence results interpreted by computer artificial intelligence technology more accurate.
[0078] 4. Western blotting to verify the function of anti-Ri human-mouse chimeric antibody
[0079] One dish of 293T cells overexpressing Nova-1, one dish of 293T cells overexpressing Nova-2, and one dish of empty pCDNA3.1 cells were collected, lysed using RIPA lysis buffer, centrifuged to obtain the supernatant, and labeled as Nova-1-pCDNA3.1, Nova-2-pCDNA3.1, and pCDNA3.1, and the protein concentration was determined using the BCA method; then the whole bacterial lysis solution of prokaryotic Nova-1 and Nova-2 constructed in Example 1 before and after induction was taken, and the above four proteins were respectively taken for gel electrophoresis. After the electrophoresis, the membrane transfer condition was 300 mA, Wet transfer was performed for 90 minutes; 5% skim milk powder was used for blocking at room temperature for 1 hour; Ri-3F5 human-mouse chimeric antibody (concentration of 0.1 mg / mL) and commercial Nova-2 antibody (manufacturer: proteintech, concentration of 0.6 mg / mL) diluted 1:1000 were incubated on the transferred PVDF membrane, and incubated overnight at 4°C; the next day, TBST was used for washing 3 times, 5 minutes each time; HRP-labeled goat anti-human / goat anti-rabbit secondary antibody (manufacturer: Jackson) was added and incubated at room temperature for 1 hour; TBST was used for washing 3 times, 5 minutes each time; ECL chemiluminescent solution was added for color development and photography, and the results are shown as follows Figure 7 shown.
[0080] The results show that the modified Ri-3F5 human-mouse chimeric antibody can recognize both Nova-1 and Nova-2 proteins in overexpressed cells, and can also recognize Nova-1 and Nova-2 proteins after prokaryotic induced expression. Compared with commercial antibodies, it has obvious humanized species advantages and can be used as a serum substitute to meet the needs of long-term detection reagents.
[0081] The monoclonal antibody of the present invention can be used for both quantification of protein concentration and determination of antibody titer, and the incubation conditions in the immunoblotting method are completely the same as those of the sample to be tested, thus solving the technical problem that the current mouse mono / polyclonal antibodies cannot be used as reference products in the diagnostic kit.
[0082] The above contents are only for explaining the technical idea of the present invention and cannot be used to limit the protection scope of the present invention. Any changes made on the basis of the technical solution in accordance with the technical idea proposed by the present invention shall fall within the protection scope of the claims of the present invention.
Claims
1. Anti-Ri monoclonal antibody, It is characterized in that Designated as humanized monoclonal antibody 3F5, it includes a light chain and a heavy chain; The variable region of the heavy chain includes three heavy chain complementary determining regions CDR1, CDR2 and CDR3, the amino acid sequence of the heavy chain complementary determining region CDR1 is shown in SEQ ID NO.1, the amino acid sequence of the heavy chain complementary determining region CDR2 is shown in SEQ ID NO.2, and the amino acid sequence of the heavy chain complementary determining region CDR3 is shown in SEQ ID NO.3; The variable region of the light chain includes three light chain complementary determining regions CDR1, CDR2 and CDR3, the amino acid sequence of the light chain complementary determining region CDR1 is shown in SEQ ID NO.4, the amino acid sequence of the light chain complementary determining region CDR2 is shown in SEQ ID NO.5, and the amino acid sequence of the light chain complementary determining region CDR3 is shown in SEQ ID NO.
6.
2. The anti-Ri monoclonal antibody according to claim 1, It is characterized in that The amino acid sequence of the heavy chain variable region of the humanized monoclonal antibody 3F5 is shown in SEQ ID NO.7, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO.
8.
3. The anti-Ri monoclonal antibody according to claim 2, It is characterized in that The nucleotide sequence encoding the heavy chain variable region of the humanized monoclonal antibody 3F5 is shown in SEQ ID NO.9; the nucleotide sequence encoding the light chain variable region of the humanized monoclonal antibody 3F5 is shown in SEQ ID NO.
10.
4. The anti-Ri monoclonal antibody according to claim 1, It is characterized in that The monoclonal antibody comprises a light chain having a complementarity determining region of an amino acid sequence that is at least 75% identical to the sequence of the variable region of the light chain, and the complementary structural domain of the light chain retains the ability to bind to the Ri protein; the monoclonal antibody comprises a heavy chain having a complementarity determining region of an amino acid sequence that is at least 75% identical to the sequence of the variable region of the heavy chain, and the complementary structural domain of the heavy chain retains the ability to bind to the Ri protein.
5. A carrier, It is characterized in that The vector comprises the nucleotide sequence of the anti-Ri monoclonal antibody according to claim 1.
6. A host cell, It is characterized in that The host cell comprises the vector according to claim 5.
7. Use of the anti-Ri monoclonal antibody according to any one of claims 1 to 4, the vector according to claim 5 or the host cell according to claim 6 in the preparation of a reagent / kit for detecting Ri protein.
8. Use of the anti-Ri monoclonal antibody according to any one of claims 1 to 4, the vector according to claim 5, or the host cell according to claim 6 in the preparation of a reagent / kit for diagnosis and / or prognosis of human paraneoplastic movement disorders.
9. A method for detecting Nova-1 protein / peptide or Nova-2 protein / peptide, It is characterized in that The biological sample is contacted with the anti-Ri monoclonal antibody according to any one of claims 1 to 4 to detect the Nova-1 protein / peptide or the Nova-2 protein / peptide in the biological sample.
10. The method for detecting Nova-1 protein / peptide or Nova-2 protein / peptide according to claim 9, It is characterized in that The biological sample includes plasma, whole blood, serum, tissue, cell or tissue and cell lysate containing Nova-1 protein / polypeptide or Nova-2 protein / polypeptide.
Citation Information
Patent Citations
Methods for diagnosing a form of ataxia and compounds for use in the method
CA2290711A1
Anti-human receptor-type protein tyrosine phosphatase sigma antibody
CN103703372A
Monoclonal antibody of anti-SARS-CoV-2 nucleocapsid protein and application
CN112225797A
Method for detecting paratumor syndrome related symbolic antibodies
CN113252906A
Monoclonal antibody of Nova-1 protein, product thereof and method for detecting Nova-1 protein
CN118255884A
